IC
KRSA

Ikarian Capital’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Ikarian Capital’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,768
Closed -$585K – 158
2022
Q1 		$585K Buy
3,768
+178
+5% +$4.29K 0.08% 125
2021
Q4 		$866K Hold
3,590
– – 0.13% 104
2021
Q3 		$1.54M Sell
3,590
-52
-1% -$3.4K 0.11% 139
2021
Q2 		$1.99M Buy
3,642
+1,499
+70% +$93.9K 0.16% 127
2021
Q1 		$836K Buy
+2,143
New +$161K 0.03% 241

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Ikarian Capital's KRSA Position: Q2 2022 in Review

Ikarian Capital sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2022, closing a stake of 3,768 shares — an estimated $585K sold.

Ikarian Capital first reported a position in KRSA in Q1 2021 and held it in 5 quarters. The position peaked at $1.99M in Q2 2021. 36 funds tracked by Wall St. Rank hold KRSA as of Q2 2022.

  • Ikarian Capital reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 3,768 Korsana Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $585K.
  • Ikarian Capital first reported a position in Korsana Biosciences, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Korsana Biosciences, Inc. Common Stock position peaked at $1.99M in Q2 2021.
  • 36 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.